SavedAdd your journal

Journals / NATURENGS / 2026 / Volume: 7 Issue: 1

Investigation of Serum Visfatin Levels in Patients with Psoriasis vulgaris: A Case-Control Study

Kısmet Kaya(FIRAT UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, THE DEPARTMENT OF DERMATOLOGY)0000-0002-2266-6319
Semih Tatlıcan(IZMIR UNIVERSITY OF ECONOMICS, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF DERMATOLOGICAL AND VENEREAL DISEASES)0000-0002-3295-0495
Özlem Gülbahar Zengin(GAZI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF BASIC MEDICAL SCIENCES, DEPARTMENT OF MEDICAL BIOCHEMISTRY)0000-0003-0450-4305
Journal
NATURENGS
Pages
—
Publication Date
2026-09-08
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings suggest that serum visfatin may be associated with psoriasis severity and selected clinical manifestations; however, its utility as a biomarker for disease activity or longitudinal disease monitoring requires further investigation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Psoriasis vulgaris is a chronic inflammatory autoimmune skin disease associated with systemic inflammation.
📊
Key Findings & Data:This prospective case-control study included 30 patients with plaque psoriasis and 22 age- and sex-matched healthy controls.
💡
Conclusion & Impact:These findings suggest that serum visfatin may be associated with psoriasis severity and selected clinical manifestations; however, its utility as a biomarker for disease activity or longitudinal disease monitoring requires further investigation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Psoriasis · metabolic syndrome · adipocytokines

Abstract

Psoriasis vulgaris is a chronic inflammatory autoimmune skin disease associated with systemic inflammation. Visfatin is a multifunctional adipocytokine that plays a key role in immune regulation, inflammation, and angiogenesis. This study aimed to investigate serum visfatin levels in patients with plaque psoriasis and assess their associations with disease severity and clinical features, including nail and joint involvement. This prospective case-control study included 30 patients with plaque psoriasis and 22 age- and sex-matched healthy controls. Serum visfatin levels were measured using an enzyme-linked immunosorbent assay (ELISA). Disease severity was assessed using the Psoriasis Area and Severity Index (PASI) Clinical features, including nail and joint involvement, were recorded. The groups were comparable in terms of age and sex. Serum visfatin levels were significantly higher in patients with psoriasis compared with controls (14.5 ± 4.6 vs. 8.1 ± 3.9 ng/mL, p < 0.001). In the psoriasis group, serum visfatin levels strongly and positively correlated with PASI scores (r = 0.80, p < 0.001). Notably, serum visfatin levels were significantly elevated in patients with joint involvement compared with those without (17.9 ± 2.8 vs. 13.8 ± 4.6 ng/mL, p = 0.037) and in patients with nail involvement compared with those without (16.5 ± 4.05 vs. 12.9 ± 4.5 ng/mL, p = 0.039). No significant association was found between visfatin levels and disease duration (p = 0.157). Serum visfatin levels were significantly elevated in patients with psoriasis and were strongly associated with disease severity and clinical features, including nail and joint involvement. These findings suggest that serum visfatin may be associated with psoriasis severity and selected clinical manifestations; however, its utility as a biomarker for disease activity or longitudinal disease monitoring requires further investigation.

🔖

Cite This Article

Kaya, K., Tatlıcan, S., Zengin, Ö. G. (2026). Investigation of Serum Visfatin Levels in Patients with Psoriasis vulgaris: A Case-Control Study. NATURENGS, Volume: 7 Issue: 1. https://doi.org/10.46572/naturengs.1931218

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (30)

  1. Boehncke, W.H., and Schön, M.P., (2015). Psoriasis. Lancet, 386(9997), 983–994.
  2. Damiani, G., Bragazzi, N.L., Karimkhani Aksut, C., Wu, D., Alicandro, G., McGonagle, D., Guo, C., Dellavalle, R., Grada, A., Wong, P., La Vecchia, C., Tam, L.S., Cooper, K.D., and Naghavi, M., (2021). The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. Frontiers in Medicine, 8, 743180.
  3. Kimmel, G.W., and Lebwohl, M., (2018). Psoriasis: Overview and Diagnosis. Evidence-Based Psoriasis: Diagnosis and Treatment, 1–16.
  4. Tashiro, T., and Sawada, Y., (2022). Psoriasis and Systemic Inflammatory Disorders. International Journal of Molecular Sciences, 23(8), 4457.
  5. Gisondi, P., Fostini, A.C., Fossà, I., Girolomoni, G., and Targher, G., (2018). Psoriasis and the metabolic syndrome. Clinics in Dermatology, 36(1), 21–28.
  6. Griffiths, C.E.M., Armstrong, A.W., Gudjonsson, J.E., and Barker, J.N.W.N., (2021). Psoriasis. Lancet, 397(10281), 1301–1315.
  7. Rendon, A., and Schäkel, K., (2019). Psoriasis Pathogenesis and Treatment. International Journal of Molecular Sciences, 20(6), 1475.
  8. Eder, L., Haddad, A., Rosen, C.F., Lee, K.A., Chandran, V., Cook, R., and Gladman, D.D., (2016). The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. Arthritis & Rheumatology, 68(4), 915–923.
  9. McGonagle, D., Tan, A.L., and Benjamin, M., (2009). The nail as a musculoskeletal appendage—implications for an improved understanding of the link between psoriasis and arthritis. Dermatology, 218(2), 97–102.
  10. Nakajima, H., Nakajima, K., Tarutani, M., Morishige, R., and Sano, S., (2011). Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients. Archives of Dermatological Research, 303(6), 451–455.
  11. Wong, Y., Nakamizo, S., Tan, K.J., and Kabashima, K., (2019). An Update on the Role of Adipose Tissues in Psoriasis. Frontiers in Immunology, 10, 1507.
  12. Kiełbowski, K., Bakinowska, E., Ostrowski, P., Pala, B., Gromowska, E., Gurazda, K., Dec, P., Modrzejewski, A., and Pawlik, A., (2023). The Role of Adipokines in the Pathogenesis of Psoriasis. International Journal of Molecular Sciences, 24(7), 6390.
  13. Clemente-Suárez, V.J., Redondo-Flórez, L., Beltrán-Velasco, A.I., Martín-Rodríguez, A., Martínez-Guardado, I., Navarro-Jiménez, E., Laborde-Cárdenas, C.C., and Tornero-Aguilera, J.F., (2023). The Role of Adipokines in Health and Disease. Biomedicines, 11(5), 1290.
  14. Audrito, V., Messana, V.G., and Deaglio, S., (2020). NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation. Frontiers in Oncology, 10, 358.
  15. Pedro, W.J.S., Barbosa Júnior, F.V., Alves, F.N.B.R., Braga, L.V., Alves, L.R., Afonso, J.P.R., Silva, I.O., Silva, C.H.M., Vencio, S., Capodaglio, P., Oliveira, L.V.F., and Freitas Júnior, W.R., (2025). Role of Adipokines Chemerin, Visfatin, and Omentin in Obesity and Their Inflammatory and Metabolic Implications. Biomedicines, 13(10), 2321.
  16. Chiricozzi, A., Raimondo, A., Lembo, S., Fausti, F., Dini, V., Costanzo, A., Monfrecola, G., Balato, N., Ayala, F., Romanelli, M., and Balato, A., (2016). Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Review of Clinical Immunology, 12(12), 1299–1308.
  17. Kong, Y., Zhang, S., Wu, R., Su, X., Peng, D., Zhao, M., and Su, Y., (2019). New insights into different adipokines in linking the pathophysiology of obesity and psoriasis. Lipids in Health and Disease, 18(1), 171.
  18. Song, Q., Xu, P., Xiao, Q., Zhang, C., and Mao, Y., (2025). Crosstalk between white adipose tissue and skin: Unraveling its role in psoriasis pathogenesis (Review). Molecular Medicine Reports, 31(6), 169.
  19. Matwiejuk, M., Kulczyńska-Przybik, A., Łukaszuk, B., Myśliwiec, H., Myśliwiec, P., Chabowski, A., Mroczko, B., and Flisiak, I., (2025). The Role of Visfatin/NAMPT in the Pathogenesis of Psoriasis. Metabolites, 15(9), 590.
  20. Mercurio, L., Morelli, M., Scarponi, C., Scaglione, G.L., Pallotta, S., Avitabile, D., Albanesi, C., and Madonna, S., (2021). Enhanced NAMPT-Mediated NAD Salvage Pathway Contributes to Psoriasis Pathogenesis by Amplifying Epithelial Auto-Inflammatory Circuits. International Journal of Molecular Sciences, 22(13), 6860.
  21. Chyl-Surdacka, K.M., Bartosińska, J., Kowal, M., Przepiórka-Kosińska, J., Krasowska, D., and Chodorowska, G., (2020). Assessment of visfatin concentrations in the serum of male psoriatic patients in relation to metabolic abnormalities. Advances in Clinical and Experimental Medicine, 29(1), 79–84.
  22. Zou, Q., Si, J., Guo, Y., Yu, J., and Shi, H., (2021). Association between serum visfatin levels and psoriasis and their correlation with disease severity: a meta-analysis. Journal of International Medical Research, 49(3), 3000605211002381.
  23. Ismail, S.A., and Mohamed, S.A., (2012). Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. British Journal of Dermatology, 167(2), 436–439.
  24. Okan, G., Baki, A.M., Yorulmaz, E., Doğru-Abbasoğlu, S., and Vural, P., (2016). Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity. Journal of Clinical Laboratory Analysis, 30(4), 284–289.
  25. Gerdes, S., Osadtschy, S., Rostami-Yazdi, M., Buhles, N., Weichenthal, M., and Mrowietz, U., (2012). Leptin, adiponectin, visfatin and retinol-binding protein-4—mediators of comorbidities in patients with psoriasis?. Experimental Dermatology, 21(1), 43–47.
  26. Dağdelen, D., Karadag, A.S., Kasapoğlu, E., Wang, J.V., and Erman, H., (2020). Correlation of metabolic syndrome with serum omentin-1 and visfatin levels and disease severity in psoriasis and psoriatic arthritis. Dermatologic Therapy, 33(6), e14378.
  27. Bai, F., Zheng, W., Dong, Y., Wang, J., Garstka, M.A., Li, R., An, J., and Ma, H., (2017). Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget, 9(1), 1266–1278.
  28. Coban, M., Tasli, L., Turgut, S., Özkan, S., Tunç Ata, M., and Akın, F., (2016). Association of Adipokines, Insulin Resistance, Hypertension and Dyslipidemia in Patients with Psoriasis Vulgaris. Annals of Dermatology, 28(1), 74–79.
  29. Sereflican, B., Goksugur, N., Bugdayci, G., Polat, M., and Haydar Parlak, A., (2016). Serum Visfatin, Adiponectin, and Tumor Necrosis Factor Alpha (TNF-α) Levels in Patients with Psoriasis and their Correlation with Disease Severity. Acta Dermatovenerologica Croatica, 24(1), 13–19.
  30. Martínez-Morcillo, F.J., Cantón-Sandoval, J., Martínez-Navarro, F.J., Cabas, I., Martínez-Vicente, I., Armistead, J., Hatzold, J., López-Muñoz, A., Martínez-Menchón, T., Corbalán-Vélez, R., Lacal, J., Hammerschmidt, M., García-Borrón, J.C., García-Ayala, A., Cayuela, M.L., Pérez-Oliva, A.B., García-Moreno, D., and Mulero, V., (2021). NAMPT-derived NAD+ fuels PARP1 to promote skin inflammation through parthanatos cell death. PLoS Biology, 19(11), e3001455.